Fresenius Medical Care, the world’s leading provider of products and services for people with chronic kidney failure, will offer the Seraph 100 Microbind Affinity Blood Filter from ExThera Medical Corporation in several European countries as of now. Both companies have signed a co-marketing and distribution agreement, effective in January 2021 and covering Belgium, Denmark, France, Germany, Italy, Luxembourg, the Netherlands, Norway, Sweden and the United Kingdom.
ExThera Medical’s Seraph 100 adsorber is used in critical care for the extracorporeal removal of pathogens from the bloodstream and can be operated with Fresenius Medical Care acute dialysis machines. Similar to the dialysis process, the blood is purified by pumping it through the filter. The Seraph 100 has been CE-certified since 2019 for the reduction of pathogens during bloodstream infections, in addition to therapy with anti-infectives.
“With the innovative adsorber technology from ExThera Medical, we are strengthening our offering in the field of critical care solutions, which is one of the key areas of the company’s strategy 2025,” said Dr Katarzyna Mazur-Hofsäß, Fresenius Medical Care’s CEO for Europe, Middle East and Africa. “Bloodstream infections often lead to kidney, lung or multiorgan failure. A treatment with the Seraph 100 can eliminate more than 90 percent of the pathogens in the patient’s blood for every pass through the filter. And the first treatment results of its use with COVID-19 patients are very promising.”
“We are very excited to partner with Fresenius Medical Care to broaden European availability of the Seraph 100,” said Bob Ward, Founder and CEO of ExThera Medical. “This distribution agreement ensures as many patients as possible will have access to a therapy that can help critically ill patients suffering from pathogen-oriented bloodstream infection.”
Fresenius Medical Care Ventures, the venture capital unit of Fresenius Medical Care, has a financial stake in ExThera Medical since 2016.
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.5 million patients worldwide regularly undergo dialysis treatment. Through its network of 4,073 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 349,167 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
ExThera Medical Corporation develops and commercializes extracorporeal blood filtration therapies, including the Seraph 100 Microbind Affinity Blood Filter for removing a broad range of harmful substances from the blood in a broad area of care: Hospitals, clinics, on the battlefield, or for pandemics. Exthera Medical has decades of experience in the development and manufacture of blood-contacting implants, devices, and the biomaterial technologies that make them work. With a growing body of data from independent clinical studies, participation in the DARPA Dialysis-Like Therapeutics program, and from successful clinical use in the US and EU, the company is well positioned to serve healthcare professionals and patients alike.
For more information visit the Company’s website at www.extheramedical.com.
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.